share_log

康方生物-B(09926)与正大天晴订立派安普利治疗肝细胞癌的III期注册试验物料及服务总采购协议

Kangfang Biological-B (09926) and Chia Tai Tianqing entered into a general procurement agreement for materials and services for the phase III registration trial of ampouli for the treatment of hepatocellular carcinoma

Zhitong Finance ·  Sep 20, 2022 22:40

According to the Zhitong Finance App, Kangfang Biology-B (09926) announced that on September 20, 2022, Tianqing Kangfang (a subsidiary of the company) signed a general procurement agreement for materials and services with Chia Tai Tianqing for the treatment of hepatocellular carcinoma. Based on this, Tianqing Kangfang agreed to purchase and Chia Da Tianqing agreed to provide clinical materials and clinical services.

According to the general procurement agreement for materials and services, Tianqing Kangfang will procure and Chia Tai Tianqing will provide: certain drugs and clinical pharmaceutical materials (including but not limited to reagents and control drugs); and certain clinical trial services for the phase III registration trial relating to the treatment of hepatocellular carcinoma with empiperidine.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment